This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.Patients eligible for this study must have had a lumpectomy with tumor-free specimen margins and axillary node dissection with pathologically-negative axillary nodes. The largest tumor diameter, by pathological examination of the resected specimen, must be < 1 cm. If the pathologic tumor size is indeterminable from the report, then the maximum clinical and mammographic tumor sizes must both be < 1 cm. If a tumor pathologically consists of both an invasive component and an intraductal component, then the maximum diameter of both components when measured together must be < 1 cm. Finally, patients are eligible if a carcinoma pathologically < 1 cm in size is detected in association with a benign lesion of any size. Patients in this study will be randomly assigned to one of three groups: lumpectomy and breast radiation plus placebo, lumpectomy and breast radiation plus tamoxifen, or lumpectomy, tamoxifen and no breast radiation.
Showing the most recent 10 out of 638 publications
